Bachmann, P.; Frahm, N.; Debus, J.L.; Mashhadiakbar, P.; Langhorst, S.E.; Streckenbach, B.; Baldt, J.; Heidler, F.; Hecker, M.; Zettl, U.K.
Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. Pharmaceutics 2022, 14, 592.
https://doi.org/10.3390/pharmaceutics14030592
AMA Style
Bachmann P, Frahm N, Debus JL, Mashhadiakbar P, Langhorst SE, Streckenbach B, Baldt J, Heidler F, Hecker M, Zettl UK.
Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. Pharmaceutics. 2022; 14(3):592.
https://doi.org/10.3390/pharmaceutics14030592
Chicago/Turabian Style
Bachmann, Paula, Niklas Frahm, Jane Louisa Debus, Pegah Mashhadiakbar, Silvan Elias Langhorst, Barbara Streckenbach, Julia Baldt, Felicita Heidler, Michael Hecker, and Uwe Klaus Zettl.
2022. "Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy" Pharmaceutics 14, no. 3: 592.
https://doi.org/10.3390/pharmaceutics14030592
APA Style
Bachmann, P., Frahm, N., Debus, J. L., Mashhadiakbar, P., Langhorst, S. E., Streckenbach, B., Baldt, J., Heidler, F., Hecker, M., & Zettl, U. K.
(2022). Prevalence and Severity of Potential Drug–Drug Interactions in Patients with Multiple Sclerosis with and without Polypharmacy. Pharmaceutics, 14(3), 592.
https://doi.org/10.3390/pharmaceutics14030592